Trials / Completed
CompletedNCT01196546
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
Multi-center, Open-label, 24-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin 50/500 or 50/1000 mg Twice Daily in Patients With T2DM Inadequately Controlled With Metformin
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 161 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vildagliptin/metformin |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-09-08
- Last updated
- 2017-08-01
Locations
8 sites across 1 country: Thailand
Source: ClinicalTrials.gov record NCT01196546. Inclusion in this directory is not an endorsement.